Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: ALLOVIRPAR

Market Cap 49.21M 42.92M 39.71M 37.28M 69.7M 4.64B 70.19M 471M 183M 2.28B 185M 181M 7.94B P/E 2023
-0.37x
P/E 2024 -0.82x
Enterprise Value -69.08M -60.25M -55.74M -52.33M -97.83M -6.51B -98.52M -661M -256M -3.2B -259M -254M -11.14B EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
-
Yield 2023 *
-
Yield 2024 -
1 day+3.74%
Current month-51.89%
Current year-51.89%
3 years 4.55
Extreme 4.55
87.17
5 years 4.55
Extreme 4.55
607.43
10 years 4.55
Extreme 4.55
1,126.08

Financials

2023 2024
Net sales - -
Net income -190M -166M -154M -144M -270M -17.96B -272M -1.82B -706M -8.83B -715M -699M -30.72B -58.77M -51.26M -47.42M -44.52M -83.23M -5.54B -83.82M -563M -218M -2.72B -221M -216M -9.48B
Net Debt -157M -137M -126M -119M -222M -14.76B -223M -1.5B -581M -7.25B -587M -575M -25.25B -118M -103M -95.45M -89.61M -168M -11.16B -169M -1.13B -439M -5.48B -444M -434M -19.08B
Logo ALLOVIRPAR
AlloVir, Inc. is an allogeneic T cell immunotherapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company’s proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. Its technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. Its lead product candidate, posoleucel, is a multi-VST therapy that targets six viruses: adenovirus (BKV), cytomegalovirus (EBV), human herpesvirus 6 (HHV-6) and JC virus (JCV). Its proprietary VST manufacturing platform enables the rapid, robust and reproducible generation of single-virus and multi-virus specific cell therapeutic candidates for clinical use.
Employees
6
Sector
-
Date Price Change Volume
18/06/26 4.720 $ +3.74% 235,548
17/06/26 4.550 $ +4.12% 82,457
16/06/26 4.370 $ +2.34% 45,120
15/06/26 4.270 $ -1.39% 83,947
12/06/26 4.330 $ -0.69% 34,257
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
  1. Stock Market
  2. Stocks
  3. ALVR Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!